Effects of lowering LDL cholesterol on progression of kidney disease.

Effects of lowering LDL cholesterol on progression of kidney disease.

Lowering LDL cholesterol reduces the risk of developing atherosclerotic events in CKD, but the effects of such treatment on progression of kidney disease remain uncertain. Here, 6245 participants with CKD (not on dialysis) were randomly assigned to simvastatin (20 mg) plus ezetimibe (10 mg) daily or...

ver descrição completa

Detalhes bibliográficos
Principais autores:	Haynes, R, Lewis, D, Emberson, J, Reith, C, Agodoa, L, Cass, A, Craig, J, de Zeeuw, D, Feldt-Rasmussen, B, Fellström, B, Levin, A, Wheeler, D, Walker, R, Herrington, W, Baigent, C, Landray, M
Formato:	Journal article
Idioma:	English
Publicado em:	2014

Registros relacionados

Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation
por: Storey, B, et al.
Publicado em: (2017)

The effect of lowering LDL cholesterol on vascular access patency: post hoc analysis of the Study of Heart and Renal Protection.
por: Herrington, W, et al.
Publicado em: (2014)

Cost-effectiveness of lowering LDL cholesterol with statins and ezetimibe in chronic kidney disease
por: Mihaylova, B, et al.
Publicado em: (2019)

The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.
por: Baigent, C, et al.
Publicado em: (2011)

The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.
por: Baigent, C, et al.
Publicado em: (2011)

Effect on non-vascular outcomes of lowering LDL cholesterol in patients with chronic kidney disease: Results from the study of heart and renal protection
por: Reith, C, et al.
Publicado em: (2017)

Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials
por: Cholesterol Treatment Trialists' Collaboration, et al.
Publicado em: (2016)

Effect on non-vascular outcomes of lowering LDL cholesterol in patients with chronic kidney disease: results from the Study of Heart and Renal Protection
por: C. Reith, et al.
Publicado em: (2017-05-01)

Smoking and Adverse Outcomes in Patients With CKD: The Study of Heart and Renal Protection (SHARP)
por: Staplin, N, et al.
Publicado em: (2015)

Evaluating the contribution of the cause of kidney disease to prognosis in CKD: results from the Study of Heart and Renal Protection (SHARP).
por: Haynes, R, et al.
Publicado em: (2014)

Evaluating the contribution of the cause of kidney disease to prognosis in ckd: Results from the Study of Heart and Renal Protection (SHARP)
por: Haynes, R, et al.
Publicado em: (2014)

Benefits of lowering cholesterol in chronic kidney disease Reply
por: Baigent, C, et al.
Publicado em: (2011)

Smoking and adverse outcomes in patients With CKD: the Study of Heart and Renal Protection (SHARP)
por: Emberson, J, et al.
Publicado em: (2016)

Prognostic utility of estimated albumin excretion rate in chronic kidney disease: results from the Study of Heart and Renal Protection.
por: Mafham, M, et al.
Publicado em: (2017)

A policy model of cardiovascular disease in moderate-to-advanced chronic kidney disease
por: Schlackow, I, et al.
Publicado em: (2017)

Evidence for reverse causality in the association between blood pressure and cardiovascular risk in patients with chronic kidney disease
por: Herrington, W, et al.
Publicado em: (2016)

Efficacy and safety of more intensive lowering of LDL cholesterol Reply
por: Baigent, C, et al.
Publicado em: (2011)

Efficacy and safety of more intensive lowering of LDL cholesterol Reply
por: Baigent, C, et al.
Publicado em: (2011)

Study of Heart and Renal Protection (SHARP): Randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease
por: Baigent, C, et al.
Publicado em: (2010)

Use of causal diagrams to inform the analysis and interpretation of observational studies: An example from the Study of Heart and Renal Protection (SHARP)
por: Staplin, N, et al.
Publicado em: (2016)

Misleading associations between cholesterol and vascular outcomes in dialysis patients: the need for randomized trials.
por: Baigent, C, et al.
Publicado em: (2007)

Evidence for the prevention and treatment of stroke in dialysis patients
por: Herrington, W, et al.
Publicado em: (2014)

Impact of outcome adjudication in kidney disease trials: observations from the Study of Heart and Renal Protection (SHARP)
por: Herrington, WG, et al.
Publicado em: (2023)

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.
por: Baigent, C, et al.
Publicado em: (2010)

Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy.
por: Emberson, J, et al.
Publicado em: (2012)

Impact of CKD on household income
por: Morton, R, et al.
Publicado em: (2017)

Conventional and genetic evidence on the association between adiposity and chronic kidney disease
por: Zhu, P, et al.
Publicado em: (2020)

Impact of CKD on Household Income
por: Rachael L. Morton, et al.
Publicado em: (2018-05-01)

Cross-sectional associations between central and general adiposity with albuminuria: observations from 400,000 people in UK Biobank
por: Zhu, P, et al.
Publicado em: (2020)

The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials.
por: Mihaylova, B, et al.
Publicado em: (2012)

Impact of diabetes on the effects of sodium glucose co-transporter-2 (SGLT2) inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials
por: Herrington, W, et al.
Publicado em: (2022)

Campath, calcineurin inhibitor reduction and chronic allograft nephropathy (the 3C Study) – results of a randomized controlled clinical trial
por: Haynes, R, et al.
Publicado em: (2018)

Standardization of Apolipoprotein B, LDL‐Cholesterol, and Non‐HDL‐Cholesterol
por: John H. Contois, et al.
Publicado em: (2023-08-01)

Declining comorbidity-adjusted mortality rates in English patients receiving maintenance renal replacement therapy
por: Storey, B, et al.
Publicado em: (2018)

Cardiovascular mortality after intensive LDL-Cholesterol lowering: Does baseline LDL-Cholesterol really matter?
por: Safi U. Khan, et al.
Publicado em: (2020-03-01)

Should we reduce blood cholesterol to prevent cardiovascular disease among patients with chronic renal failure?
por: Baigent, C, et al.
Publicado em: (2000)

Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy.
por: Cholesterol Treatment Trialists' (CTT) Collaboration, et al.
Publicado em: (2012-01-01)

Conventional and genetic evidence on the association between adiposity and CKD
por: Zhu, P, et al.
Publicado em: (2020)

Cystatin C and risk of vascular and nonvascular mortality: a prospective cohort study of older men.
por: Emberson, JR, et al.
Publicado em: (2010)

Different cellular traffic of LDL-cholesterol and acetylated LDL-cholesterol leads to distinct reverse cholesterol transport pathwayss⃞
por: Ming-Dong Wang, et al.
Publicado em: (2007-03-01)